Preparing US healthcare insurance for high-cost curative therapies

Preparing US healthcare insurance for high-cost curative therapies

Matthew Majewski
Life Sciences

In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.

To read the full article, click here.